The business strategies of companies involved in chiral drug development were cast into doubt in October after Eli Lilly (Indianapolis, IL) decided not to pursue the development of R-fluoxetine ...

Imine reductases can catalyze reductive amination reactions to produce chiral amines, however ... to ceramides and are employed as targeted drugs and diagnostic biomarkers, however, their ...

Developing racemic (mixed-enantiomer) drugs is on the way out, industry analysts say, because pharmaceutical companies must evaluate the individual enantiomers and the combination. "Nearly every ...

Yu's next goal is to adapt his new system to create chiral molecules ... alcohols and amines, three other major chemical groups critical to drug synthesis. The new method with ketones—and ...